Nievescarey8030
Hemodialysis is the most common mode of therapy worldwide for chronic kidney disease (CKD) and is used as a life-sustaining therapy for most of the patients. Studies proved that dialysis affects the Quality of life (QOL) of patients. Health-related quality of life has been increasingly recognized as an important medical outcome in patients with CKD. Kidney disease quality of life short form (KDQOL-SF™) is developed by RAND to assess the QOL in CKD patients. This study was conducted to translate and validate the questionnaire KDQOL-SF™ in Malayalam.
A cross sectional study was conducted among the patients who were undergoing dialysis in Sree Gokulam Medical College and Research foundation, Trivandrum. The translation was done according the specifications given by RAND. A sample of 112 patients studied. Statistical analysis was done for evaluating item internal consistency, item discriminant validity, equality of item-scale correlations, scale level reliability, and validity. Scale level descriptive statistics were computed.
Item internal consistency was more than 0.4 for all scales except a few. Item-level discriminant validity was 100% for almost all scales. Scale level reliability and validity were examined; all scales met the required internal consistency criteria. The overall reliability of the tool was 0.81. Scale level reliability varies from 0.71 to 0.92, which support item homogeneity and internal consistency across scales. Overall mean health rating score was 53.43 ± 11.48.
The Malayalam version of KDQOL-SF™ is reliable and valid which can be used for measuring the health-related quality of life of Malayalam speaking CKD patients.
The Malayalam version of KDQOL-SF™ is reliable and valid which can be used for measuring the health-related quality of life of Malayalam speaking CKD patients.
The goal of arterio-venous fistula (AVF) creation is to achieve a well-functioning access that can be cannulated repetitively and can provide adequate flow for the dialysis. The objective of this study was to assess the role of far infrared (FIR) therapy in the unassisted maturation of newly created AVF in patients with chronic kidney disease (CKD).
In this prospective open labeled randomised control trial, 107 patients were randomized. Participants in the control arm received oral clopidogrel 75 mg once daily for 30 days along with isometric hand exercise, whereas those in the test arm received FIR therapy twice weekly, 40 min session each, for 4 weeks. A biopsy from venous end was taken during fistula surgery. Doppler study of AVF was done at the end of the 4
and 12
week to assess AVF. Vascular access guidelines proposed by National Kidney Foundation -Kidney Disease Outcomes Quality Initiative (NKF- KDOQI) in 2006 were adapted to define the maturation of AVF.
Out of 107 patients, 51 were randomizee AVF blood flow rate at the end of 3 months, though the difference in primary failure rate was statistically insignificant.
Full-house immunofluorescence in a kidney biopsy is a common observation in lupus nephritis (LN) and was previously used synonymously with the diagnosis of LN. Though a minority of the patients will develop features suggestive of SLE during follow-up, a majority of the patients will continue without any clinical or serological evidence of systemic lupus erythematosus (SLE) over time. NHWD-870 molecular weight Our aim to conduct this study was to work up the clinicopathological spectrum of these "full-house" nephropathies (FHN) which were not due to lupus nephritis.
A total of 6244 renal biopsies were evaluated at SGPGIMS Lucknow from January 2007 to December 2017 for full-house immunofluorescence. All those patients who had no clinical or serological evidence of SLE at the time of renal biopsy or at any time during follow up were included.
Among 498 patients with full house immunofluorescence, 81 patients had no clinical or serological evidence of SLE at the time of renal biopsy or at any time during follow up. The prevalence of non-lupus FHN in this study was 19.4%, and the major diagnoses were membranous nephropathy (25.9%), IgAN (22.2%), MPGN (14.8%), DPGN (12.3%), Crescentic GN (12.3%), Amyloidosis (8.6%), C1q nephropathy (3.7%).
Full-house nephropathy (FHN), not otherwise suggestive of lupus nephritis, can also be found in a number of other conditions. Non-lupus full house nephropathy is an umbrella term for such cases which do not satisfy the standard criteria of SLE. This will prevent misclassifying these patients into SLE and further prevent them from unnecessary immunosuppression protocols.
Full-house nephropathy (FHN), not otherwise suggestive of lupus nephritis, can also be found in a number of other conditions. Non-lupus full house nephropathy is an umbrella term for such cases which do not satisfy the standard criteria of SLE. This will prevent misclassifying these patients into SLE and further prevent them from unnecessary immunosuppression protocols.
Non-diabetic renal diseases (NDRDs) form an important part of disease manifestations in patients with diabetes.
This hospital-based prospective study was conducted to analyze incidence and spectrum of NDRDs in patients with diabetes with or without diabetic nephropathy (DN), effect of early specific interventions on outcome, and renal-retinal relationship in type 1 and type 2 diabetes mellitus with nephropathy. 44 Patients with T2DM with the clinical suspicion of NDRD were subjected to renal biopsy Renal biopsies were performed by using an automated biopsy gun. Tissue was processed for Light microscopy-LM and Immunofluorescence-IF. Electron Microscopy was done as and when required by reprocessing the tissue embedded in paraffin for LM. Biopsies were reported by one experienced renal pathologist.
Renal histopathology revealed that of 44 enrolled patients with clinically suspected NDRD, 61.4% had isolated NDRD, 13.6% had NDRD superimposed on DN, and 25% had isolated DN. The most common NDRDs were minimal ng NDRD by kidney biopsy facilitates initiation of specific therapy, which may lead to clinical improvement in significant number of patients.
Accurate diagnosis of underlying NDRD by kidney biopsy facilitates initiation of specific therapy, which may lead to clinical improvement in significant number of patients.
